<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="130970">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01711177</url>
  </required_header>
  <id_info>
    <org_study_id>OPM3117-Dubois/Pham</org_study_id>
    <nct_id>NCT01711177</nct_id>
  </id_info>
  <brief_title>Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma</brief_title>
  <official_title>Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université de Montréal</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glaucoma is the second leading cause of blindness among seniors in Canada. It is often
      associated with an elevated intraocular pressure (IOP), but its exact mechanism is still
      largely unknown. Some studies have shown a link between glaucoma and changes in the amount
      of oxygen in the veins of the eye. The study aims to compare the amount of oxygen in ocular
      veins among three different groups using a spectrophotometer. This instrument is linked to a
      camera and can measure the quantity of oxygen in the veins using different characteristics
      of the blood inside.

      The groups of the study are: patients without glaucoma, patients suspected of glaucoma and
      patients newly diagnosed with glaucoma. The drug the investigators are using, Travoprost
      0.004%, will only be administered to the groups suspected or diagnosed with glaucoma.
      Travoprost 0.004% is already approved for use in Quebec and is part of standard care. Ten
      patients will be recruited into each group for a total of 30 patients in this study. All
      patients for the suspected or diagnosed groups will be recruited from the Jewish General
      Hospital. Subsequently all testing will be done at the École d'optométrie, Université de
      Montréal
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Blood oxygenation</measure>
    <time_frame>1 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>For each subject, all the measurements will be done during an 1 hour appointment.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Normal control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Normal patient placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glaucoma suspect</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients with elevated Intraocular pressure higher than 18 mmHg (placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Newly diagnosed glaucoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated with Travoprost (0.04%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Normal control</arm_group_label>
    <arm_group_label>Glaucoma suspect</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>travoprost</intervention_name>
    <description>Travatan Z is administered to newly diagnosed glaucoma patient</description>
    <arm_group_label>Newly diagnosed glaucoma</arm_group_label>
    <other_name>travatan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  good systemic health

          -  irido-corneal angle open

          -  intraocular pressure more than 18 mmHg

        Exclusion Criteria:

          -  having cardiovascular problem

          -  Hypertension or diabetes

          -  under systemic medication for high blood pressure

          -  had an ocular surgery in the past
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3t1P1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Forcier, MSc</last_name>
      <phone>514-343-7468</phone>
      <email>pierre.forcier@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>Pierre Forcier, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vasile Diaconu, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oskar Kasner, md FRCSC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 19, 2012</lastchanged_date>
  <firstreceived_date>October 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Montréal</investigator_affiliation>
    <investigator_full_name>Pierre Forcier</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>primary open angle glaucoma</keyword>
  <keyword>retinal oximetry</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
